Ocaliva In NASH Manageable With Indication-Based Pricing, ICER Roundtable Suggests
Indication-specific pricing could address 'tension' between initial pricing of Ocaliva for orphan condition and later use in large patient population, according to expert roundtable convened by Institute for Clinical and Economic Review.
You may also be interested in...
The cost-effectiveness watchdog group sees the fibrosis benefit with Intercept’s obeticholic acid as supporting use in sicker NASH patients, but its overall risk-benefit ratio doesn’t merit broader use.
The Institute for Clinical and Economic Review is launching an initiative to adapt its value assessment approach to orphan and ultra-orphan drugs, including a possible consideration of what should be a fair return on investment for manufacturers.
Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.